

**P&T Motion History**  
**Calcitonin Gene-Related Peptide Inhibitors (CGRP)- migraine prevention**

Drugs reviewed	Motion	Date reviewed	Surveillance accepted as adequate	Reiteration of prior motion	Decision
<b>atogepant</b> eptinezumab erenumab fremanezumab galcanezumab rimegepant ubrogepant zavegepant	<p>After considering the evidence of safety and efficacy for the treatment of migraine prophylaxis, I move that atogepant, eptinezumab, erenumab, fremanezumab, galcanezumab, and rimegepant are safe and efficacious for the treatment of their approved indications. These drugs can be subject to therapeutic interchange in the Washington preferred drug list, within respective modes of delivery and approved indications.</p> <p>After considering the evidence of safety and efficacy for the treatment of acute migraine, I move that rimegepant and ubrogepant are safe and efficacious for the treatment of their approved indications. Rimegepant and ubrogepant can be subject to therapeutic interchange with each other in the Washington preferred drug list.</p> <p>Motion: MacKay            2<sup>nd</sup>: Corsilles</p>	February 15, 2023	NA	NA	Passed unanimous

**Bold** = new this update

Grey = not enough evidence to be fully reviewed